ABCB 1‐mediated docetaxel resistance reversed by erastin in prostate cancer
The FEBS Journal · 2024
DOI: 10.1111/febs.17135 ↗Kurz gefasst
Fachartikel in der Zeitschrift The FEBS Journal, 2024. Verfasst von Fangfang Chen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institution of Life Sciences, Chongqing Medical University, China. Hauptthemen laut MEDLINE: Docetaxel, Drug Resistance, Neoplasm, ATP Binding Cassette Transporter, Subfamily B, Xenograft Model Antitumor Assays. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Docetaxel (Doc) currently serves as the primary first‐line treatment for patients with castrate‐resistant prostate cancer (CRPC). Erastin, a small molecule compound, can trigger inhibition of the cystine–glutamate reverse transport system and other pathways, leading to iron‐dependent cell death (ferroptosis). Beyond its role in inducing cancer cell death, erastin demonstrates potential when combined with chemotherapy drugs to heighten cancer cell drug susceptibility. However, the augmentation by erastin of the effects of Doc treatment on prostate cancer, and the underlying mechanisms involved, remain unclear. In the present study, we determined the role and the underlying molecular mechanism of erastin against CRPC. The results showed that CRPC cell lines were resistant to Doc, and the expression of ferroptosis‐related factors in drug‐resistant cell lines was downregulated. Erastin, in synergy with Doc, exerts a pro‐apoptotic effect. Erastin significantly inhibited the activity of ATP‐binding cassette subfamily B member 1 (ABCB1) but did not change its protein expression and localization. Finally, in mice, erastin treatment dramatically reduced tumor growth in vivo . Taken together, our findings demonstrate that erastin enhances Doc‐induced apoptosis to a certain extent and reverses Doc resistance in prostate cancer by inhibiting the activity of multidrug‐resistant protein ABCB1.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institution of Life Sciences, Chongqing Medical University, China.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Chen, F., Wu, S., Kuang, N., Zeng, Y., Li, M., & Xu, C. (2024). ABCB 1‐mediated docetaxel resistance reversed by erastin in prostate cancer. The FEBS Journal. https://doi.org/10.1111/febs.17135
Vancouver
Chen F, Wu S, Kuang N, Zeng Y, Li M, Xu C. ABCB 1‐mediated docetaxel resistance reversed by erastin in prostate cancer. The FEBS Journal. 2024. doi:10.1111/febs.17135
BibTeX
@article{Chen2024,
author = {Chen, Fangfang and Wu, Shiqi and Kuang, Ni and Zeng, Yan and Li, Meixi and Xu, Chen},
title = {ABCB 1‐mediated docetaxel resistance reversed by erastin in prostate cancer},
journal = {The FEBS Journal},
year = {2024},
doi = {10.1111/febs.17135}
}
EUVIMED